

# Thalassemia - Pipeline Review, H2 2020

<https://marketpublishers.com/r/TDF1AE74848EN.html>

Date: August 2020

Pages: 215

Price: US\$ 2,000.00 (Single User License)

ID: TDF1AE74848EN

## Abstracts

Thalassemia - Pipeline Review, H2 2020

### Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2020, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

### Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 15, 6, 1, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

## **Reasons to Buy**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Thalassemia - Overview

Thalassemia - Therapeutics Development

Thalassemia - Therapeutics Assessment

Thalassemia - Companies Involved in Therapeutics Development

Thalassemia - Drug Profiles

Thalassemia - Dormant Projects

Thalassemia - Discontinued Products

Thalassemia - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Thalassemia, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020 (Contd..1), H2 2020  
Products under Development by Companies, H2 2020 (Contd..2), H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Thalassemia - Pipeline by Acceleron Pharma Inc, H2 2020  
Thalassemia - Pipeline by Agios Pharmaceuticals Inc, H2 2020  
Thalassemia - Pipeline by Alllife Medical Science and Technology Co Ltd, H2 2020  
Thalassemia - Pipeline by Aruvant Sciences Inc, H2 2020  
Thalassemia - Dormant Projects, H2 2020  
Thalassemia - Dormant Projects, H2 2020 (Contd..1), H2 2020  
Thalassemia - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Thalassemia, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Routes of Administration, H2 2020  
Number of Products by Stage and Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

Accelaron Pharma Inc  
Agiros Pharmaceuticals Inc  
Alllife Medical Science and Technology Co Ltd  
Aruvant Sciences Inc  
ASC Therapeutics Inc  
Beam Therapeutics Inc  
bluebird bio Inc  
Cell Source Inc  
Cetya Therapeutics Inc  
CRISPR Therapeutics AG  
CSL Ltd  
Disc Medicine Inc  
DisperSol Technologies LLC  
EdiGene Inc  
Editas Medicine Inc  
EmeraMed Ltd  
Errant Gene Therapeutics LLC  
ExCellThera Inc  
Fulcrum Therapeutics Inc  
Gamida Cell Ltd  
Gilead Sciences Inc

Imara Inc  
Invenux LLC  
Ionis Pharmaceuticals Inc  
Kymab Ltd  
Merganser Biotech Inc  
Nanjing Transthera Biosciences Co Ltd  
Nanomedic Inc  
Orchard Therapeutics Plc  
Phoenicia Biosciences Inc  
Rare Partners Srl  
Regenacy Pharmaceuticals LLC  
Sangamo Therapeutics Inc  
Sanquin Plasma Products BV  
Shanghai Bioray Laboratory Inc  
Silence Therapeutics Plc  
Syros Pharmaceuticals Inc  
Vera Therapeutics Inc  
Vifor Pharma AG

## I would like to order

Product name: Thalassemia - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/TDF1AE74848EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TDF1AE74848EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970